Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
The collaboration aims to bolster healthcare entrepreneurship
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subscribe To Our Newsletter & Stay Updated